Radotinib-d6
Radotinib-d6 is deuterium labeled Radotinib. Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells. Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases[1][2].
Product Specifications
CAS Number
2754051-83-5
Product Name Alternative
IY-5511-d6
UNSPSC
12352005
Target
Apoptosis; Bcr-Abl; Isotope-Labeled Compounds; JAK; Prion Protein; STAT
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Epigenetics; JAK/STAT Signaling; Neuronal Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Infection; Neurological Disease
Solubility
10 mM in DMSO
Smiles
O=C(NC1=CC(C(F)(F)F)=CC(N2C=C(C)N=C2)=C1)C3=C([2H])C([2H])=C(C([2H])([2H])[2H])C(NC4=NC=CC(C5=NC=CN=C5)=N4)=C3[2H]
Molecular Formula
C27H15D6F3N8O
Molecular Weight
536.54
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human IgM (Immunoglobulin Mu Heavy Chain) (B-Cell Marker) (R1/69), CF568 conjugate, 0.1mg/mL
